- $8.72bn
- $8.22bn
- $108.78m
Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77
Brief: Immunogen Says German Federal Cartel Office Approved Merger With Abbvie Unconditionally
Ambrx Biopharma surges on J&J's buyout announcement
Street View: BioMarin-Elliott settlement likely eases investor frustration
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout (updated)
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout
AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
Brief: FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
U.S. RESEARCH ROUNDUP- Carvana, Constellation Brands, CSG Systems International
Brief: Immunogen Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Microstrategy, Salesforce
U.S. STOCKS ON THE MOVE-Ford Motor, REX, Weibo
AbbVie clinches the drug patent-cliff dismount
U.S. STOCKS ON THE MOVE-Packaging Corp of America, ImmunoGen, SilverBow Resources
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-General Motors, Synopsys, Enphase Energy
ImmunoGen jumps on $10.1 billion acquisition deal with AbbVie
Brief: Abbvie To Acquire Immunogen, Including Cancer Therapy Elahere®, Expanding Solid Tumor Portfolio
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio (updated)